American Society of Hematology. (2017).
FDA Approves Pembrolizumab for Refractory or Relapsed Classical Hodgkin Lymphoma.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-pembrolizumab-for-refractory-or-relapsed-classical-hodgkin-lymphoma.
American Society of Hematology.
"FDA Approves Pembrolizumab for Refractory or Relapsed Classical Hodgkin Lymphoma." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-pembrolizumab-for-refractory-or-relapsed-classical-hodgkin-lymphoma
(label-accessed November 04, 2025).
"American Society of Hematology."
FDA Approves Pembrolizumab for Refractory or Relapsed Classical Hodgkin Lymphoma, 04 Nov. 2025 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-pembrolizumab-for-refractory-or-relapsed-classical-hodgkin-lymphoma.
